MX9802005A - Moleculas de adn circular con origen de replicacion condicional, su proceso de preparacion y su utilizacion en terapia genica. - Google Patents

Moleculas de adn circular con origen de replicacion condicional, su proceso de preparacion y su utilizacion en terapia genica.

Info

Publication number
MX9802005A
MX9802005A MX9802005A MX9802005A MX9802005A MX 9802005 A MX9802005 A MX 9802005A MX 9802005 A MX9802005 A MX 9802005A MX 9802005 A MX9802005 A MX 9802005A MX 9802005 A MX9802005 A MX 9802005A
Authority
MX
Mexico
Prior art keywords
replication
gene therapy
dna molecule
preparing same
circular dna
Prior art date
Application number
MX9802005A
Other languages
English (en)
Other versions
MXPA98002005A (es
Inventor
Joel Crouzet
Fabienne Soubrier
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9482580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9802005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9802005A publication Critical patent/MX9802005A/es
Publication of MXPA98002005A publication Critical patent/MXPA98002005A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • C07K14/501Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/69Increasing the copy number of the vector
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invencion se refiere a una molécula de ADN de forma circular,util en terapia génica, que comprende al menos una secuencia nucleica de interés, caracterizada porque la region que permite su replicacion comprende un origen de replicacion donde la funcionalidad en una célula huésped requiera la presencia de al menos una proteína específica y extraña para dicha célula huésped. Esta tiene igualmente por objetivo un procedimiento de preparacion correspondiente, de las células que incorporan las moléculas de ADN y sus usos en terapia génica.
MXPA/A/1998/002005A 1995-09-15 1998-03-13 Moleculas de adn circular con origen de replicacion condicional, su proceso de preparación y su utilización en terapia génica MXPA98002005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510825A FR2738842B1 (fr) 1995-09-15 1995-09-15 Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
FR95/10825 1995-09-15

Publications (2)

Publication Number Publication Date
MX9802005A true MX9802005A (es) 1998-08-30
MXPA98002005A MXPA98002005A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
EP0850310B1 (fr) 2004-12-15
EP1724354A3 (fr) 2008-10-29
ATE284966T1 (de) 2005-01-15
JP3818665B2 (ja) 2006-09-06
EP1508620A1 (fr) 2005-02-23
ES2281721T3 (es) 2007-10-01
DE69634043T2 (de) 2005-08-18
IL173399A0 (en) 2006-06-11
EP1508620B1 (fr) 2007-01-24
PT850310E (pt) 2005-05-31
SK34798A3 (en) 1998-11-04
FR2738842B1 (fr) 1997-10-31
TWI231826B (en) 2005-05-01
PT1724354E (pt) 2011-03-09
NO323975B1 (no) 2007-07-30
JP2007325603A (ja) 2007-12-20
ES2233975T3 (es) 2005-06-16
IL123641A (en) 2006-06-11
CZ294525B6 (cs) 2005-01-12
BR9610511B1 (pt) 2010-10-19
NO981044L (no) 1998-03-10
ATE492642T1 (de) 2011-01-15
US20090130674A1 (en) 2009-05-21
KR100522369B1 (ko) 2006-10-24
ZA967640B (en) 1997-03-25
US20010014476A1 (en) 2001-08-16
JP4585435B2 (ja) 2010-11-24
DE69636878T2 (de) 2007-11-08
CA2229307A1 (fr) 1997-03-20
BR9610511A (pt) 1999-01-26
DE69636878D1 (de) 2007-03-15
JP2000501281A (ja) 2000-02-08
IL207348A0 (en) 2010-12-30
ATE352630T1 (de) 2007-02-15
IL123641A0 (en) 1998-10-30
NO981044D0 (no) 1998-03-10
HUP9900018A1 (hu) 1999-04-28
CZ78898A3 (cs) 1998-06-17
PT1508620E (pt) 2007-05-31
EP1724354A2 (fr) 2006-11-22
DK1724354T3 (da) 2011-04-04
CA2229307C (fr) 2013-06-11
DE69638314D1 (de) 2011-02-03
HUP9900018A3 (en) 2001-10-29
AU6992496A (en) 1997-04-01
JP4756014B2 (ja) 2011-08-24
ES2357098T3 (es) 2011-04-18
BRPI9610511B8 (pt) 2016-11-08
JP2006136328A (ja) 2006-06-01
KR19990044683A (ko) 1999-06-25
US6977174B2 (en) 2005-12-20
EP1724354B1 (fr) 2010-12-22
IL173399A (en) 2010-11-30
DK0850310T3 (da) 2005-04-25
AU728231B2 (en) 2001-01-04
FR2738842A1 (fr) 1997-03-21
WO1997010343A1 (fr) 1997-03-20
US20090149406A1 (en) 2009-06-11
SK285317B6 (sk) 2006-10-05
HU224400B1 (hu) 2005-08-29
DE69634043D1 (de) 2005-01-20
DK1508620T3 (da) 2007-05-29
EP0850310A1 (fr) 1998-07-01

Similar Documents

Publication Publication Date Title
HK1082761A1 (en) Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
IL123641A0 (en) Circular dna molecule with conditional origin of replication method for preparing the same and use thereof in gene therapy
MX9800719A (es) Proteinas de transporte y sus usos.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
GEP20012559B (en) Complementary Adenoviral Vector Systems and Cells Lines
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
PT789766E (pt) Particulas quimericas do tipo papilomavirus
AU682140B2 (en) Multidrug resistance gene
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
GR3031229T3 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
WO1999027094A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
WO1999018202A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND cDNAs ENCODING THESE PROTEINS
WO1999018199A3 (en) cDNAs CODING FOR HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS
WO2004024938A3 (en) Β1,4-n-acetylgalactosaminyltransferases, nucleic acids and methods of use thereof
ATE288476T1 (de) Herstellung von proteinen
AU728231C (en) Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy
MX9709596A (es) Adn catal ??tico.

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
HC Change of company name or juridical status
FG Grant or registration
GB Transfer or rights